Synergy of Topotecan in Combination with Vincristine for Treatment of Pediatric Solid Tumor Xenografts

摘要: Topotecan and vincristine were evaluated alone or in combination against 13 independent xenografts 1 vincristine-resistant derivative, representing childhood neuroblastoma ( n = 6), rhabdomyosarcoma 5), brain tumors 3). was given by i.v. bolus on a schedule found previously to be optimal. Drug administered daily for 5 days 2 consecutive weeks with cycles repeated every 21 over period of 8 weeks. Doses topotecan ranged from 0.16 1.5 mg/kg simulate clinically achievable lactone plasma systemic exposures. Vincristine 7 at fixed dose mg/kg. Given as single agent, induced complete responses (CRs) all mice bearing two rhabdomyosarcomas (Rh28 Rh30) some CRs Rh12-bearing (57%) but relatively few